R&G PharmaStudies Co., Ltd. (SHE:301333)
China · Delayed Price · Currency is CNY 50.70
+3.38 (7.14%)
At close: Aug 4, 2026
R&G PharmaStudies Market Cap
R&G PharmaStudies has a market cap or net worth of 4.87 billion as of August 4, 2026. Its market cap has decreased by -8.65% in one year.
Market Cap
4.87B
Enterprise Value
3.16B
Revenue
896.26M
Ranking
n/a
PE Ratio
36.18
Stock Price
50.70
ChartMarket Cap Chart
Since August 2, 2022, R&G PharmaStudies's market cap has decreased from 5.40B to 4.87B, a decrease of -9.88%. That is a compound annual growth rate of -2.56%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 4, 2026 | 4.87B | -14.10% |
| Dec 31, 2025 | 5.67B | 19.12% |
| Dec 31, 2024 | 4.76B | -23.17% |
| Dec 29, 2023 | 6.19B | 25.30% |
| Dec 30, 2022 | 4.94B | -8.52% |
| Aug 2, 2022 | 5.40B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Novogene | 5.15B |
| Shouyao Holdings (Beijing) Co., LTD. | 4.80B |
| Beijing Konruns Pharmaceutical | 4.69B |
| Suzhou Fengbei Biotech Stock | 4.67B |
| Xiangxue Pharmaceutical | 4.62B |
| Shenzhen Weiguang Biological Products | 4.52B |
| ChemPartner PharmaTech | 4.46B |
| PharmaResources (Shanghai) | 4.37B |